Altheos Lands $12,500,000 Series A Financing Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=80635cd1-8d9f-4215-98d7-7b63f3f804ed&Preview=1 -
Date
2/9/2012 -
Company Name
Altheos -
Mailing Address
601 Gateway Blvd. South San Francisco, CA 94080 -
Company Description
Altheos, Inc. is focused on the development of a best-in-class next-generation eye drop treatment for glaucoma. The lead compound, ATA907, is a selective rho-kinase (ROCK) inhibitor developed specifically for topical treatment of glaucoma which Altheos licensed from a Japanese pharmaceutical company. -
Website
http://www.altheos.net -
Transaction Type
Venture Equity -
Transaction Amount
$12,500,000 -
Transaction Round
Series A -
Proceeds Purposes
The increase of our Series A round allows us the opportunity to advance our lead candidate to phase 3 trials. -
M&A Terms
-
Venture Investor
Bay City Capital -
Venture Investor
Novo A/S -
Venture Investor
Canaan Partners -
Venture Investor
Undisclosed
